FDA Approves Biogen’s SPINRAZA™ (nusinersen) for Spinal Muscular Atrophy
The SMA Foundation is excited to share the news that the U.S. Food and Drug Administration (FDA) approved Biogen’s SPINRAZA™ (nusinersen) under Priority Review for the treatment of Spinal Muscular Atrophy (SMA) in pediatric and adult patients. SPINRAZA is the first and only treatment approved for SMA. (Please see http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm534611.htm for additional information.)
SPINRAZA offers new hope for the SMA patients. We are truly grateful to patients and families who participated in the SPINRAZA clinical trials, the clinicians who conducted the trials, the FDA in rapidly reviewing and approving this drug, and Ionis and Biogen in collaboration with academic investigators for the development of SPINRAZA. This was truly a community effort which has led to the first approved effective treatment for SMA.
For more information on how to obtain the drug please visit www.spinraza.com